Biomea Fusion, Inc. — Investor Relations & Filings
Filings indexed
266
across all filing types
Latest filing
2026-04-28
Regulatory Filings
Country
US
United States of America
Listing
US
BMEA
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecule drugs for the treatment of diabetes and obesity. The company's pipeline is centered on advancing novel therapies designed to address metabolic diseases. Key investigational products include icovamenib, a menin inhibitor being evaluated in the COVALENT-111 Phase II study for type 2 diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist in Phase I clinical trials for obesity. Biomea Fusion aims to develop treatments that can potentially offer durable benefits, including combination strategies with existing therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Biomea Fusion, Inc. (0001840439) (Filer) | 2026-04-28 | English | |
| 8-K - Biomea Fusion, Inc. (0001840439) (Filer) | 2026-03-24 | English | |
| 8-K - BIOMEA FUSION, INC. (0001840439) (Filer) | 2026-02-25 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-12 | English | |
| SCHEDULE 13G/A Filing | 2026-02-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 37991652 | 8-K - Biomea Fusion, Inc. (0001840439) (Filer) | 2026-04-28 | English | ||
| 33035026 | 8-K - Biomea Fusion, Inc. (0001840439) (Filer) | 2026-03-24 | English | ||
| 32899600 | 8-K - BIOMEA FUSION, INC. (0001840439) (Filer) | 2026-02-25 | English | ||
| 32013206 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32013223 | SCHEDULE 13G Filing | 2026-02-12 | English | ||
| 32013229 | SCHEDULE 13G/A Filing | 2026-02-06 | English | ||
| 32013211 | 5 Filing | 2026-02-06 | English | ||
| 13362387 | 8-K | 2026-01-14 | English | ||
| 13362389 | S-8 | 2026-01-06 | English | ||
|
2025
6 filings
| |||||
| 13362388 | 4 | 2025-12-15 | English | ||
| 13362391 | 4 | 2025-12-04 | English | ||
| 13362392 | 4 | 2025-12-02 | English | ||
| 13362393 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13362395 | Major Shareholding Notification 2025 | 2025-11-07 | English | ||
| 13362394 | 10-Q | 2025-11-04 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Biomea Fusion, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34049/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34049 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34049 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34049 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34049}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Biomea Fusion, Inc. (id: 34049)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.